US-based investment fund giant OrbiMed has announced the successful raising of over USD 4.3 billion for its latest private investment funds. The capital will be distributed among OrbiMed Private Investments IX, OrbiMed Asia Partners V, and OrbiMed Royalty & Credit Opportunities IV, reflecting the firm’s commitment to expanding its reach in the healthcare sector.
Fund Allocation and Investment Strategy
According to a spokesperson quoted by BioPharmaDive.com, the funds will be allocated as follows: USD 1.865 billion to OrbiMed Private Investments IX, USD 1.71 billion to OrbiMed Royalty and Credit Opportunities IV, and USD 751 million to OrbiMed Asia Partners V. This strategic distribution underscores OrbiMed’s diversified approach to investment in the healthcare industry.
OrbiMed Asia Partners V: Focus on Growth Equity Investments
OrbiMed Asia Partners V, first established in 2022, is specifically targeted at growth equity investments in healthcare companies, with a focus on meeting the increasing demand for higher quality, affordable healthcare in the People’s Republic of China (PRC) and India. This initiative aligns with the growing healthcare needs in these regions and OrbiMed’s goal to support innovative solutions.
Investment in China-Based Life Sciences Firms
Fineline Info & Tech data indicates that OrbiMed has been actively investing in China-based life sciences firms throughout 2023. Notably, OrbiMed led a USD 150 million private placement for Gracell Biotechnologies Inc. (NASDAQ: GRCL), a specialist in chimeric antigen receptor (CAR) T therapy, in August. This investment highlights OrbiMed’s focus on supporting cutting-edge biotechnologies and therapeutic advancements.-Fineline Info & Tech
